Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

被引：4
|
作者：
Mok, Tony
Cheng, Ying
Zhou, Xiangdong
Lee, Ki Hyeong
Nakagawa, Kazuhiko
Niho, Seiji
Tsuji, Fumito
Rosell, Rafael
Jaime, Jesus Corral
Migliorino, Maria Rita
Pluzanski, Adam
Linke, Rolf Gerhard
Sbar, Eric
Wang, Tao
Wu, Yi-Long
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[2] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
[3] Third Mil Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[4] Chungbuk Natl Univ Hosp, Chungcheong, South Korea
[5] Kinki Univ, Fac Med, Osakasayama, Japan
[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[7] SFJ Pharmaceut Grp Inc, Osaka, Japan
[8] Catalan Inst Oncol, Barcelona, Spain
[9] Hosp Virgen Rocio, Seville, Spain
[10] Azienda Osped San Camilo Forlanini, Rome, Italy
[11] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[12] Inst Oncol, Warsaw, Poland
[13] SFJ Pharmaceut Inc, Pleasanton, CA USA
[14] Pfizer Inc, Collegeville, PA USA
[15] Pfizer Inc, Groton, CT 06340 USA
[16] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[17] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 18期
关键词：
D O I：
10.1200/JCO.2017.35.18_suppl.LBA9007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9007
引用
收藏
页数：3
相关论文
共 50 条
  • [31] First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
    Marth, Christian
    Moore, Richard G.
    Bidzinski, Mariusz
    Pignata, Sandro
    Ayhan, Ali
    Rubio, M. Jesus
    Beiner, Mario
    Hall, Marcia
    Vulsteke, Christof
    Braicu, Elena Ioana
    Sonoda, Kenzo
    Wu, Xiaohua
    Frentzas, Sophia
    Mattar, Andre
    Lheureux, Stephanie
    Chen, Xiaojun
    Hasegawa, Kosei
    Magallanes-Maciel, Manuel
    Choi, Chel Hun
    Shalkova, Mariia
    Kaen, Diego
    Wang, Peng-Hui
    Berger, Regina
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Yao, Lili
    Orlowski, Robert
    Khemka, Vivek
    Gilbert, Lucy
    Makker, Vicky
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
  • [32] FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002
    Osamu, Ishimoto
    Kobayashi, Kunihiko
    Inoue, Akira
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Saijo, Yasuo
    Gemma, Akihiko
    Morita, Satoshi
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    ANNALS OF ONCOLOGY, 2010, 21 : 11 - 11
  • [33] LUX-Lung 7: A Phase lib, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
    Park, K.
    Tan, E. -H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J.
    Mok, T.
    Kim, M.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S118
  • [34] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [35] Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Mitsuoka, Shigeki
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumira, Tomohiro
    Matusura, Kuniomi
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    Hirata, Kazuto
    LUNG CANCER, 2015, 90 (01) : 65 - 70
  • [36] Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
    Lu, S.
    Zhou, J.
    Jian, H.
    Wu, L.
    Cheng, Y.
    Fan, Y.
    Fang, J.
    Chen, G.
    Zhang, Z.
    Lv, D.
    Jiang, L.
    Wu, R.
    Jin, X.
    Zhang, X.
    Zhang, J.
    Sun, G.
    Huang, D.
    Cui, J.
    Guo, R.
    Ding, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
  • [37] Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan
    Ohe, Y.
    Ichinose, Y.
    Nishiwaki, Y.
    Yamamoto, N.
    Negoro, S.
    Duffield, E.
    Jiang, H.
    Saijo, N.
    Mok, T.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial
    Chu, Tianqing
    Zhong, Hua
    Yu, Zhuang
    Wang, Jing
    Zhao, Yanqiu
    Mu, Xiaoqian
    Yu, Xinmin
    Shi, Xun
    Shi, Qingming
    Guan, Maojing
    Ding, Cuimin
    Geng, Nan
    Qian, Jialin
    Han, Baohui
    CANCER COMMUNICATIONS, 2025,
  • [39] FIRST-LINE GEFITINIB TREATMENT FOR ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATION: MULTICENTER PHASE II TRIAL CJLSG0901
    Takahashi, K.
    Saito, H.
    Yamamoto, M.
    Kojima, E.
    Yokoyama, T.
    Sugino, Y.
    Kimura, T.
    Ogasawara, T.
    Suzuki, R.
    Hasegawa, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 434 - 434
  • [40] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
12345